HRP20140419T1 - Molekule za vezanje koje mogu neutralizirati virus bjesnoä†e i njihova uporaba - Google Patents

Molekule za vezanje koje mogu neutralizirati virus bjesnoä†e i njihova uporaba Download PDF

Info

Publication number
HRP20140419T1
HRP20140419T1 HRP20140419TT HRP20140419T HRP20140419T1 HR P20140419 T1 HRP20140419 T1 HR P20140419T1 HR P20140419T T HRP20140419T T HR P20140419TT HR P20140419 T HRP20140419 T HR P20140419T HR P20140419 T1 HRP20140419 T1 HR P20140419T1
Authority
HR
Croatia
Prior art keywords
rabies virus
seq
chain variable
variable region
binding
Prior art date
Application number
HRP20140419TT
Other languages
English (en)
Inventor
Alexander Berthold Hendrik Bakker
Willem Egbert Marissen
Cornelis Adriaan De Kruif
Robert Arjen Kramer
Original Assignee
Crucell Holland B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland B.V. filed Critical Crucell Holland B.V.
Publication of HRP20140419T1 publication Critical patent/HRP20140419T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)

Claims (4)

1. Farmaceutski pripravak koji sadrži barem dvije molekule za vezanje koje imaju sposobnost neutraliziranja virusa bjesnoće koje su sposobne reagirati sa različitim, nekonkurentnim epitopima virusa bjesnoće, naznačen time da prva molekula za vezanje koja neutralizira virus bjesnoće je sposobna reagirati sa epitopom koji sadrži aminokiseline 226-231 G proteina virusa bjesnoće, a druga molekula za vezanje koja neutralizira virus bjesnoće je sposobna reagirati sa epitopom koji se nalazi na antigenom mjestu III koja sadrži aminokiseline 330-338 G proteina virusa bjesnoće.
2. Farmaceutski pripravak koji sadrži dvije molekule za vezanje koje imaju sposobnost neutraliziranja virusa bjesnoće koje su sposobne vezati se za različite, ne-konkurentne epitope virusa bjesnoće, naznačen time da pripravak sadrži: prvu molekulu za vezanje koja neutralizira virus bjesnoće koja je sposobna vezati se na epitop koji sadrži aminokiseline 226-231 G proteina virusa bjesnoće, te navedeno antitijelo koje neutralizira virus bjesnoće sadrži: varijabilnu regiju teškog lanca koja sadrži aminokiselinsku sekvencu SEQ ID NO: 273, i varijabilnu regiju lakog lanca koja sadrži aminokiselinsku sekvencu SEQ ID NO: 275, i drugu molekulu za vezanje koja neutralizira virus bjesnoće koja je sposobna vezati se na epitop smješten u antigenom mjestu III koja sadrži aminokiseline 330-338 G proteina virusa bjesnoće.
3. Farmaceutski pripravak prema zahtjevu 2, naznačen time da druga molekula za vezanje koja neutralizira virus bjesnoće sadrži: varijabilnu regiju teškog lanca koja sadrži SEQ ID NO: 29 i varijabilnu regiju lakog lanca koja sadrži SEQ ID NO: 53; ili varijabilnu regiju teškog lanca koja sadrži SEQ ID NO: 35 i varijabilnu regiju lakog lanca koja sadrži SEQ ID NO: 59; ili varijabilnu regiju teškog lanca koja sadrži SEQ ID NO: 39 i varijabilnu regiju lakog lanca koja sadrži SEQ ID NO: 63; ili varijabilnu regiju teškog lanca koja sadrži SEQ ID NO: 40 i varijabilnu regiju lakog lanca koja sadrži SEQ ID NO: 64; ili varijabilnu regiju teškog lanca koja sadrži SEQ ID NO: 41 i varijabilnu regiju lakog lanca koja sadrži SEQ ID NO: 65; ili varijabilnu regiju teškog lanca koja sadrži SEQ ID NO: 47 i varijabilnu regiju lakog lanca koja sadrži SEQ ID NO: 71.
4. Farmaceutski pripravak prema zahtjevu 2, naznačen time da je prva molekula za vezanje virusa bjesnoće IgG i druga molekula za vezanje virusa bjesnoće je IgG.
HRP20140419TT 2004-05-27 2014-05-08 Molekule za vezanje koje mogu neutralizirati virus bjesnoä†e i njihova uporaba HRP20140419T1 (hr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US57502304P 2004-05-27 2004-05-27
EP2004050943 2004-05-27
EP2004051661 2004-07-29
EP2004052286 2004-09-23
EP2004052772 2004-11-03
EP2005050310 2005-01-25
EP2005050953 2005-03-03

Publications (1)

Publication Number Publication Date
HRP20140419T1 true HRP20140419T1 (hr) 2014-06-06

Family

ID=34968690

Family Applications (3)

Application Number Title Priority Date Filing Date
HR20110320T HRP20110320T1 (hr) 2004-05-27 2011-05-03 Molekule za vezanje koje mogu neutralizirati virus bjesnoće i njihova uporaba
HRP20130750TT HRP20130750T1 (hr) 2004-05-27 2013-08-07 Postupak identifikacije molekula za vezanje koje mogu neutralizirati virus bjesnoä†e
HRP20140419TT HRP20140419T1 (hr) 2004-05-27 2014-05-08 Molekule za vezanje koje mogu neutralizirati virus bjesnoä†e i njihova uporaba

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HR20110320T HRP20110320T1 (hr) 2004-05-27 2011-05-03 Molekule za vezanje koje mogu neutralizirati virus bjesnoće i njihova uporaba
HRP20130750TT HRP20130750T1 (hr) 2004-05-27 2013-08-07 Postupak identifikacije molekula za vezanje koje mogu neutralizirati virus bjesnoä†e

Country Status (23)

Country Link
US (5) US7579446B2 (hr)
EP (3) EP2314621B1 (hr)
JP (1) JP4768730B2 (hr)
KR (2) KR101228157B1 (hr)
CN (5) CN1961002B (hr)
AT (1) ATE501171T1 (hr)
AU (1) AU2005250163B2 (hr)
BR (1) BRPI0511479C1 (hr)
CA (1) CA2568162C (hr)
CU (1) CU23719A3 (hr)
CY (1) CY1111550T1 (hr)
DK (1) DK1749029T3 (hr)
EA (1) EA010785B1 (hr)
ES (2) ES2468021T3 (hr)
HK (3) HK1094705A1 (hr)
HR (3) HRP20110320T1 (hr)
IL (3) IL179586A (hr)
MX (1) MXPA06013482A (hr)
NZ (2) NZ580607A (hr)
PL (3) PL2314620T3 (hr)
PT (3) PT2314621E (hr)
RS (2) RS53269B (hr)
WO (1) WO2005118644A2 (hr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
ES2295639T3 (es) * 2002-06-13 2008-04-16 Crucell Holland B.V. Agonistas del receptor ox40=(=cd134) y uso terapeutico descripcion.
AU2003256299A1 (en) 2002-07-01 2004-01-19 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
CN101537180B (zh) 2002-07-18 2016-02-10 莫鲁斯有限公司 抗体混合物的重组生产
ES2408582T3 (es) 2003-05-30 2013-06-21 Merus B.V. Biblioteca de Fab para la preparación de una mezcla de anticuerpos
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
NZ543635A (en) 2003-06-25 2008-05-30 Crucell Holland Bv Human C-type lectin: a suitable target molecule for binding molecules, particularly immunoconjugates, in the diagnosis, prevention and/or treatment of myeloid neoplastic diseases such as AML and CML
AU2004260884B2 (en) * 2003-07-22 2009-11-19 Crucell Holland B.V. Binding molecules against SARS-coronavirus and uses thereof
RS53269B (en) 2004-05-27 2014-08-29 Crucell Holland B.V. BINDING MOLECULES WHICH MAY NEUTRALIZE FRAGILE VIRUS AND USE
WO2006040322A1 (en) * 2004-10-12 2006-04-20 Crucell Holland B.V. Binding molecules for treatment and detection of cancer
ATE507242T1 (de) 2005-05-12 2011-05-15 Crucell Holland Bv Wirtszellenspezifische bindungsmoleküle, die dazu in der lage sind, viren zu neutralisieren, und anwendungen davon
AU2006290736B2 (en) * 2005-09-15 2011-09-15 Crucell Holland B.V. Method for preparing immunoglobulin libraries
WO2007038407A2 (en) 2005-09-23 2007-04-05 The Regents Of The University Of California Compositions and methods for treating nervous system disorders
EP2024394B1 (en) 2006-06-06 2014-11-05 Crucell Holland B.V. Human binding molecules having killing activity against enterococci and staphylococcus aureus and uses thereof
CA2881717C (en) 2006-06-06 2018-06-12 Cecilia Anna Wilhelmina Geuijen Human binding molecules having killing activity against staphylococci and uses thereof
MY170607A (en) * 2006-09-07 2019-08-20 Crucell Holland Bv Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
KR101522036B1 (ko) * 2006-12-05 2015-05-20 크루셀 홀란드 비.브이. 액체 항-광견병 항체 조성물
CN102838673B (zh) 2007-06-25 2016-05-11 艾斯巴技术-诺华有限责任公司 修饰抗体的方法和具有改善的功能性质的修饰抗体
JO2913B1 (en) * 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
WO2010132532A1 (en) 2009-05-15 2010-11-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services B cell surface reactive antibodies
US8821879B2 (en) 2009-09-04 2014-09-02 Xoma Technology Ltd. Anti-botulism antibody coformulations
WO2011041518A1 (en) * 2009-10-02 2011-04-07 The Regents Of The University Of California Monoclonal antibodies
CN101696242B (zh) * 2009-10-26 2011-12-28 中国人民解放军南京军区军事医学研究所 人源抗狂犬病毒中和抗体Fab及其制备方法和应用
EP2521735A2 (en) * 2010-01-04 2012-11-14 Indian Immunologicals Limited Recombinant human bivalent diabody against rabies virus and uses thereof
EP2537931B1 (en) * 2010-02-19 2016-10-19 Japan Science And Technology Agency Antiviral abzyme
KR101903931B1 (ko) 2010-03-01 2018-10-02 바이엘 헬스케어 엘엘씨 조직 인자 경로 억제제 (ｔｆｐｉ)에 대한 최적화된 모노클로날 항체
EP3511342B1 (en) 2010-03-10 2024-01-17 Genmab A/S Monoclonal antibodies against c-met
EP3135692B8 (en) * 2010-06-16 2019-03-20 University of Pittsburgh - Of the Commonwealth System of Higher Education Antibodies to endoplasmin and their use
WO2012128508A2 (ko) * 2011-03-18 2012-09-27 (주)셀트리온 광견병 바이러스를 중화시킬 수 있는 결합 분자
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
CN103998059B (zh) * 2011-09-30 2016-01-20 赛特瑞恩股份有限公司 用于中和狂犬病病毒的结合分子
PT2838918T (pt) 2012-04-20 2019-08-23 Merus Nv Métodos e meios para a produção de moléculas heterrodiméricas do tipo ig
CN102924571A (zh) * 2012-10-29 2013-02-13 复旦大学 狂犬病毒糖蛋白与核蛋白的抗原表位多肽及其筛选、鉴定方法与应用
KR101739313B1 (ko) * 2013-12-12 2017-05-24 (주)셀트리온 광견병 바이러스를 중화시킬 수 있는 결합 분자
CN103954777A (zh) * 2014-05-20 2014-07-30 北京凯思百奥科技发展有限公司 一种狂犬病病毒单克隆抗体及其应用
RU2549971C1 (ru) * 2014-07-01 2015-05-10 Федеральное казённое учреждение здравоохранения Ставропольский научно-исследовательский противочумный институт Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Способ консервации иммунопероксидазного конъюгата
CN104761640A (zh) * 2015-02-03 2015-07-08 中国食品药品检定研究院 具有中和活性的抗狂犬病病毒单克隆抗体的制备及应用
US10722571B2 (en) * 2015-06-10 2020-07-28 Celltrion Inc. Rabies virus G protein epitope, and rabies virus neutralising binding molecule that binds specifically thereto
CN109069627A (zh) 2016-01-14 2018-12-21 纪念斯隆-凯特琳癌症中心 对foxp3衍生肽特异性的t细胞受体样抗体
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
RU2718835C2 (ru) * 2017-12-29 2020-04-15 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Нейтрализующее моноклональное антитело, связывающееся с гликопротеином g вируса бешенства, фрагменты днк, кодирующие указанное антитело, и антигенсвязывающий фрагмент
WO2019227039A1 (en) * 2018-05-24 2019-11-28 Lankenau Institute For Medical Research Compositions comprising antibodies to rabies virus and the uses thereof
WO2020029860A1 (zh) * 2018-08-09 2020-02-13 北京智仁美博生物科技有限公司 针对狂犬病病毒的双特异性抗体及其用途
AU2020281380B2 (en) * 2019-05-30 2024-04-11 Shandong Boan Biotechnology Co., Ltd. Antibody or chimeric antigen receptor which targets claudin 18.2
CN111171145B (zh) * 2020-01-21 2021-11-05 兰州生物制品研究所有限责任公司 一种抗狂犬病病毒单克隆抗体、制备方法及用途
EP4320165A1 (en) * 2021-04-09 2024-02-14 Sorrento Therapeutics, Inc. Antigen binding proteins that bind ror1
CN114397453B (zh) * 2022-03-25 2022-06-07 江苏美克医学技术有限公司 新型冠状病毒突变株的检测试剂盒及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
ATE99958T1 (de) * 1989-06-08 1994-01-15 Wistar Inst Monoklonale antikoerper zur behandlung nach einem kontakt mit tollwutvirus.
US6248574B1 (en) 1989-12-13 2001-06-19 Avigdor Shaffermann Polypeptides selectively reactive with antibodies against human immunodeficiency virus and vaccines comprising the polypeptides
DE4006630A1 (de) 1990-03-03 1991-09-12 Behringwerke Ag Humane monoklonale antikoerper gegen tollwutviren, ihre herstellung und verwendung
NL9101953A (nl) 1991-11-21 1993-06-16 Seed Capital Investments Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen.
US5624949A (en) 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
JP2001512560A (ja) * 1996-10-08 2001-08-21 ユー―ビスイス ベスローテン フェンノートシャップ 標的に対し特異的な親和性を有するペプチドおよびタンパク質の選択のための方法および手段
ATE536417T1 (de) 1999-04-15 2011-12-15 Crucell Holland Bv Herstellung von rekombinanten proteinen in einer menschlichen zelle mit mindestens einem e1 adenovirus protein
US20040013672A1 (en) * 2000-05-16 2004-01-22 Thomas Jefferson University Recombinant antibodies, and compositions and methods for making and using the same
US7071319B2 (en) * 2000-05-16 2006-07-04 Thomas Jefferson University Recombinant antibodies, and compositions and methods for making and using the same
CA2449071C (en) 2001-06-15 2008-12-16 Crucell Holland B.V. Chimaeric phages
MXPA04001609A (es) * 2001-08-21 2005-03-07 Univ Jefferson Anticuerpos recombinantes, y composiciones y metodos para elaborar y utilizar los mismos.
ES2295639T3 (es) * 2002-06-13 2008-04-16 Crucell Holland B.V. Agonistas del receptor ox40=(=cd134) y uso terapeutico descripcion.
CN101537180B (zh) * 2002-07-18 2016-02-10 莫鲁斯有限公司 抗体混合物的重组生产
US20100069614A1 (en) * 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
NZ543635A (en) 2003-06-25 2008-05-30 Crucell Holland Bv Human C-type lectin: a suitable target molecule for binding molecules, particularly immunoconjugates, in the diagnosis, prevention and/or treatment of myeloid neoplastic diseases such as AML and CML
AU2004260884B2 (en) 2003-07-22 2009-11-19 Crucell Holland B.V. Binding molecules against SARS-coronavirus and uses thereof
ES2367027T3 (es) 2004-02-27 2011-10-27 Inserm (Institut National De La Santé Et De La Recherche Medicale) Sitio de unión de la il-15 para il-15ralfa y mutantes específicos de il-15 que tienen actividad agonista/antagonista.
RS53269B (en) * 2004-05-27 2014-08-29 Crucell Holland B.V. BINDING MOLECULES WHICH MAY NEUTRALIZE FRAGILE VIRUS AND USE
AU2005303758B2 (en) 2004-11-11 2011-04-28 Crucell Holland B.V. Compositions against SARS-coronavirus and uses thereof
WO2006067122A2 (en) 2004-12-20 2006-06-29 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
EP1871803B1 (en) 2005-04-18 2013-02-20 Yeda Research And Development Company Limited Stabilized anti-hepatitis b (hbv) antibody formulations
ATE507242T1 (de) 2005-05-12 2011-05-15 Crucell Holland Bv Wirtszellenspezifische bindungsmoleküle, die dazu in der lage sind, viren zu neutralisieren, und anwendungen davon
US20090130652A1 (en) 2005-06-23 2009-05-21 Crucell Holland B.V. Optimization of West Nile Virus Antibodies
MX2008010988A (es) * 2006-02-27 2008-10-20 Elan Pharm Inc Compuestos de pirimidinil sulfonamida que inhiben la adhesion de los leucocitos mediada por vla-4.
EP2024394B1 (en) * 2006-06-06 2014-11-05 Crucell Holland B.V. Human binding molecules having killing activity against enterococci and staphylococcus aureus and uses thereof
CA2881717C (en) * 2006-06-06 2018-06-12 Cecilia Anna Wilhelmina Geuijen Human binding molecules having killing activity against staphylococci and uses thereof
MY170607A (en) * 2006-09-07 2019-08-20 Crucell Holland Bv Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
KR101522036B1 (ko) * 2006-12-05 2015-05-20 크루셀 홀란드 비.브이. 액체 항-광견병 항체 조성물

Also Published As

Publication number Publication date
CA2568162A1 (en) 2005-12-15
PT2314621E (pt) 2014-06-23
AU2005250163B2 (en) 2011-08-25
ATE501171T1 (de) 2011-03-15
IL201970A (en) 2014-06-30
CN102212132A (zh) 2011-10-12
KR20070044807A (ko) 2007-04-30
IL179586A0 (en) 2007-05-15
HRP20110320T1 (hr) 2011-05-31
NZ550366A (en) 2009-11-27
RS51847B (en) 2012-02-29
PT1749029E (pt) 2011-06-27
EP2314620B1 (en) 2013-06-05
HK1094705A1 (en) 2007-04-04
EP2314620A1 (en) 2011-04-27
DK1749029T3 (da) 2011-06-06
EA200602210A1 (ru) 2007-04-27
CA2568162C (en) 2013-04-16
JP2008508859A (ja) 2008-03-27
PL2314621T3 (pl) 2014-08-29
EP1749029A2 (en) 2007-02-07
US20100272724A1 (en) 2010-10-28
CY1111550T1 (el) 2015-08-05
US20080070799A1 (en) 2008-03-20
EA010785B1 (ru) 2008-10-30
KR101228157B1 (ko) 2013-01-31
AU2005250163A1 (en) 2005-12-15
WO2005118644A3 (en) 2006-03-09
US20100310572A1 (en) 2010-12-09
EP2314621A1 (en) 2011-04-27
CN1961002B (zh) 2011-05-18
IL225849A0 (en) 2013-06-27
US7740852B2 (en) 2010-06-22
ES2468021T3 (es) 2014-06-13
KR20130010130A (ko) 2013-01-25
HK1157680A1 (en) 2012-07-06
US8148497B2 (en) 2012-04-03
EP2314621B1 (en) 2014-03-05
HRP20130750T1 (hr) 2013-10-11
US7579446B2 (en) 2009-08-25
CN102212131B (zh) 2013-05-08
BRPI0511479A (pt) 2007-12-26
CN102212131A (zh) 2011-10-12
US9005624B2 (en) 2015-04-14
PL2314620T3 (pl) 2013-11-29
CU23719A3 (es) 2011-10-14
PL1749029T3 (pl) 2011-08-31
CN102241769B (zh) 2016-08-10
KR101456770B1 (ko) 2014-10-31
BRPI0511479C1 (pt) 2021-05-25
RS53269B (en) 2014-08-29
CN102241769A (zh) 2011-11-16
ES2426725T3 (es) 2013-10-24
CN102139106B (zh) 2014-10-08
JP4768730B2 (ja) 2011-09-07
IL179586A (en) 2013-06-27
CN1961002A (zh) 2007-05-09
PT2314620E (pt) 2013-09-02
US20070072177A1 (en) 2007-03-29
NZ580607A (en) 2011-05-27
HK1159651A1 (en) 2012-08-03
US20080226652A1 (en) 2008-09-18
WO2005118644A2 (en) 2005-12-15
MXPA06013482A (es) 2007-03-01
EP1749029B1 (en) 2011-03-09
BRPI0511479B1 (pt) 2019-01-29
CN102139106A (zh) 2011-08-03

Similar Documents

Publication Publication Date Title
HRP20140419T1 (hr) Molekule za vezanje koje mogu neutralizirati virus bjesnoä†e i njihova uporaba
CY1122505T1 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn
HRP20140760T1 (hr) Citotoksiäśni imunoglobulin
PE20071055A1 (es) Anticuerpos anti mn
CY1118037T1 (el) Αντισωματα εναντι του αβητα και h χρηση τους
RU2014149553A (ru) Биспецифические анти-vegf/анти-ang-2 антитела
PL392809A1 (pl) Przeciwciało monoklonalne przeciwko CD40 i jego część wiążąca antygen, zawierająca go kompozycja i jego zastosowanie, oraz linia komórkowa, cząsteczka kwasu nukleinowego, wektor komórka gospodarza i sposób wytwarzania
SI2542257T1 (en) Optimized monoclonal antibodies against Tissue Factor Pathway Inhibitor (TFPI)
EA200700136A1 (ru) Анти-cd154-антитела
RS52769B (sr) Kompozicije i postupci za povećanje mineralizacije kostiju
SI2573121T1 (en) IL-4 and / or IL-13 binding antibodies and their uses
EA200801509A1 (ru) Человеческие моноклональные антитела к протеинтирозинкиназе 7 ( ptk7) и способы применения антител против ptk7
JP2010521147A5 (hr)
RS53594B1 (en) PREPARAT HER2 ANTITELA
RS52782B (en) HIGH AFINITY HUMAN ANTIBODIES FOR THE HUMAN IL-4 RECEPTOR
CL2008003004A1 (es) Anticuerpo anti-esclerostina o su porción de enlace de antígeno; polinucleotido que lo codifica; vector; célula; proceso de producción; composición farmacéutica que lo comprende; método para identificar células y su uso para tratar trastornos óseos.
RU2015150149A (ru) Составы на основе биспецифических антител к il-4/il-13
RU2012131671A (ru) Способ полипептидной модификации для очистки полипептидных мультимеров
EE200700052A (et) Antikeha he v?i mitme apo-lipoproteiin B fragmendi vastu
EA201491575A1 (ru) Антитела к матриксной металлопротеиназе 9
ATE427963T1 (de) Verfahren, kits und zusammensetzungen zur entwicklung und anwendung von fur antigene niedriger immunogenizitat spezifischen monoklonalen antikírpern
ATE490314T1 (de) Verfahren zur förderung der homologen rekombination somatischer zellen und verfahren zur konstruktion eines spezifischen antikörpers
JP2018515449A5 (hr)
ATE412428T1 (de) Antigen-raster enthaltend rankl zur behandlung von knochenerkrankungen
JP2018515453A5 (hr)